Oncology Views & Analysis

Views & Analysis

Oncology

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.

Patients

ASCO 26: Three cancer survivors share lessons for the field

In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Oncology

Female cancer survivor and her grown daughter

Cancer patients don’t care where the breakthrough happened. ...

National Cancer Survivors’ Day highlighted decades of progress against cancer, but oncology faces a new challenge.

Oncology

ASCO 26: Precision medicine takes a village, with Carolyn So...

In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.

Patients

ASCO 26: War, disasters, policy compound cancer care challen...

A Friday ASCO session highlighted the challenges faced by cancer patients in situations of geopolitical crisis, as presenters called for more support.

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

ASCO 26: Three cancer survivors share lessons for the field

ASCO 2026: Chinese firms take a front seat in oncology, with...

Cancer patients don’t care where the breakthrough happened. ...

ASCO 26: Precision medicine takes a village, with Carolyn So...

ASCO 26: War, disasters, policy compound cancer care challen...

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks